Akt and p53R2, partners that dictate the progression and invasiveness of cancer

被引:47
作者
Yousefi, Bahman [1 ,2 ]
Samadi, Nasser [3 ,4 ]
Ahmadi, Yasin [3 ,4 ,5 ]
机构
[1] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Dept Biochem, Fac Med, Tabriz, Iran
[4] Tabriz Univ Med Sci, Clin Labs, Fac Med, Tabriz, Iran
[5] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
关键词
Akt; P53R2; Ribonucleotide reductase; Cancer progression; Cell cycle; PROTEIN-KINASE B/AKT; SQUAMOUS-CELL CARCINOMA; HUMAN RIBONUCLEOTIDE REDUCTASE; SUBUNIT P53R2; PHOSPHOINOSITIDE; 3-KINASE; PHOSPHORYLATED AKT; LUNG-CANCER; DNA-DAMAGE; MALIGNANT-TRANSFORMATION; RAF/MEK/ERK PATHWAY;
D O I
10.1016/j.dnarep.2014.07.001
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The serine/threonine kinase or the so-called "Akt" is a key regulatory molecule of signaling pathway that regulates various cellular processes. Many intracellular proteins are involved in the activation or inhibition of Akt signaling and the hyperactivation of Akt signaling pathway is found to be frequently involved in various types of human cancers. Furthermore, while p53R2, a p53-inducible peptide involved in the synthesis of dNTPs normally works toward suppression of cancer through elimination of reactive oxygen species (ROS), inhibition of MAPK/ERK pathway and providing dNTPs for DNA repair, the overexpression of p53R2 is reported to be associated with cancer progression and resistance to therapy. In this review article, we will discuss the situation in which cancer cells with hyperactive PI3K/Akt signaling can recruit p53R2 in favor of cancer progression and resistance to therapy. In the hyperactive state of PI3K/Akt signaling (which happens in the absence of deactivation or excess of activation), p53R2 can be used by cancer cells to promote proliferation. Therefore, the hyperactivity of PI3K/Akt pathway and elevated levels of p53R2 can give rise to highly invasive cancers. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:24 / 29
页数:6
相关论文
共 84 条
[1]   3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase [J].
Alessi, DR ;
Deak, M ;
Casamayor, A ;
Caudwell, FB ;
Morrice, N ;
Norman, DG ;
Gaffney, P ;
Reese, CB ;
MacDougall, CN ;
Harbison, D ;
Ashworth, A ;
Bownes, M .
CURRENT BIOLOGY, 1997, 7 (10) :776-789
[2]   Immunohistochemical localization of phosphorylated AKT in multiple myeloma [J].
Alkan, S ;
Izban, KF .
BLOOD, 2002, 99 (06) :2278-2279
[3]   Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth [J].
Altomare, DA ;
You, HH ;
Xiao, GH ;
Ramos-Nino, ME ;
Skele, KL ;
De Rienzo, A ;
Jhanwar, SC ;
Mossman, BT ;
Kane, AB ;
Testa, JR .
ONCOGENE, 2005, 24 (40) :6080-6089
[4]   Perturbations of the AKT signaling pathway in human cancer [J].
Altomare, DA ;
Testa, JR .
ONCOGENE, 2005, 24 (50) :7455-7464
[5]   The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells [J].
Aman, MJ ;
Lamkin, TD ;
Okada, H ;
Kurosaki, T ;
Ravichandran, KS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (51) :33922-33928
[6]   Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1β:: a role for the dual signalling pathways, Akt and Erk [J].
Amin, ARMR ;
Senga, T ;
Oo, ML ;
Thant, AA ;
Hamaguchi, M .
GENES TO CELLS, 2003, 8 (06) :515-523
[7]   Activation of AKT kinases in cancer: Implications for therapeutic targeting [J].
Bellacosa, A ;
Kumar, CC ;
Di Cristofano, A ;
Testa, JR .
ADVANCES IN CANCER RESEARCH, VOL 94, 2005, 94 :29-+
[8]  
Blackhall FH, 2003, CLIN CANCER RES, V9, P2241
[9]   PTEN, more than the AKT pathway [J].
Blanco-Aparicio, Carmen ;
Renner, Oliver ;
Leal, Juan F. M. ;
Carnero, Amancio .
CARCINOGENESIS, 2007, 28 (07) :1379-1386
[10]   The phosphoinositide 3-kinase pathway [J].
Cantley, LC .
SCIENCE, 2002, 296 (5573) :1655-1657